

Zone Industrielle de Planchy Chemin de Croix-Blanche 10 1630 Bulle - Switzerland

## Invoice n. 90000081

Document date: 18 January 2018

Ship-to address:

GLAXOSMITHKLINE EXPORT LIMITED JEBEL ALI

BRANCH PHARMACEUTICALS

P.O. Box 17136

. DUBAI

**EMIR.ARAB.UNIS** 

GLAXOSMITHKLINE TRADING SERVICES LTD

980 GREAT WEST ROAD

**BRENTFORD** 

Middlesex **TW8 9GS** 

**GRANDE BRETAGNE** 

Sold-to address:

GLAXOSMITHKLINE TRADING SERVICES LTD

980 GREAT WEST ROAD

**BRENTFORD** Middlesex **TW8 9GS** 

**GRANDE BRETAGNE** 

VAT registration no: Payer: 20000391

Your reference: OI000001075478001

Our reference: 92889095 Order date: 21 Sep 2017

Terms of delivery: FCA MOEHLIN Mode of transport: Boat - Collected

Currency: EUR

Invoice Details				
Material Code	Description	Batch Value	Quantity	Amount
CIA03691	XYZAL 5MG 30TAB RB GSK MEA	226406	33,480 EA	
	Gross Value Taric code: 30049000	623.30 EUR / 1000 EA		20,868.08
CIA03691	XYZAL 5MG 30TAB RB GSK MEA	228834	16,560 EA	
	Gross Value Taric code: 30049000	623.30 EUR / 1000 EA		10,321.85
Total Gross Value				31,189.93
Total item discount	amount			0.00
Total Net Value				31,189.93
		VAT%	VAT base	VAT
Output Tax		0,000%	31,189.93 EUR	0.00
Output Tax		0,000%	36,702.44 CHF	0.00

To be paid (VAT incl.)

31,189.93

THIRTY-ONE THOUSAND ONE HUNDRED EIGHTY-NINE EURO NINETY-THREE Payment within 60 days due net

Payment conditions:

19 Mar 2018

Latest due date:

Payment method:

Shipping remarks: Order nº .: 1547659

Delivery n°.: 81976292

Phone: +41588223306

VAT no: CHE-103.818.575 TVA





Zone Industrielle de Planchy Chemin de Croix-Blanche 10 1630 Bulle - Switzerland

# Invoice n. 9000081 Document date: 18 January 2018

Volume: 5,354.280 CD3

Material Code	Description	Batch	Quantity	Amount
		Value	Price Unit	Discount

Gross weight: 1,041.791 KG Net weight: 154.625 KG

We hereby certify that this invoice is true and correct in all respects.

VAT no: CHE-103.818.575 TVA

Zone Industrielle de Planchy Chemin de Croix-Blanche 10 1630 Bulle - Switzerland

#### **Packing List / Delivery Note** 81976292

Ship-to address

GLAXOSMITHKLINE EXPORT LIMITED JEBEL ALI

**BRANCH PHARMACEUTICALS** 

P.O. Box 17136

. DUBAI

**EMIR.ARAB.UNIS** 

Sold-to address:

GLAXOSMITHKLINE TRADING SERVICES LTD

980 GREAT WEST ROAD

**BRENTFORD** 

Middlesex

**TW8 9GS** 

UNITED KINGDOM

Shipping point address

Galliker Transport AG

Bäumlimattstrasse 7

4313 MÖHLIN

**SWITZERLAND** 

Req. delivery date:

22 Jan 2018

Customer number:

20004007

Customer purch.Order: Order number/date:

Ol000001075478001 1547659 / 21 Sep 2017

Customer VAT:

GB239820839

Terms of delivery:

FCA MOEHLIN

Means of transport:

Boat - Collected

Packages:

Pallet: 9

Loading weight:

861.791 KG

Gross HU:

1,041.791 KG

Total volume:

Net weight material:

154.625 KG

Gross material:

861.788 KG

E-GDP Information:

The product should be stored and transported according to its "Registered Storage Conditions".

The Storage Conditions on the shipping label reflect the "Warehouse temperature conditions" at which the products are stored at UCB. The warehouse temperature conditions will always be within the limits of the Registered Storage conditions.

For distribution activities, it is also acceptable to transport the product at the "Transport Conditions". Please note that those "Transport Conditions" may be broader than the "Registered Storage Conditions" only if they are supported by a set of scientific data approved by the quality unit."

SSCC (HU Identification) Material	Description Batch	Dimension Description Warehouse temperature conditions Other Storage Conditions Registered Storage Conditions	Loading weight Net weight Expiration date	Gross weight  Qty material
180325296909501334 CIA03691	Pallet 228834	80 x 120 x 110 CM XYZAL 5MG 30TAB RB GSK MEA 15-25 °C (59-77°F) Not specified Store below 30°C	99.199 17.799KG 31 Aug 2022	119.199 KG 5,760 EA
180325296909502553 CIA03691	Pallet 228834	80 x 120 x 110 CM XYZAL 5MG 30TAB RB GSK MEA 15-25 °C (59-77°F) Not specified	99.199 17.799KG 31 Aug 2022	119.199 KG 5,760 EA

Zone Industrielle de Planchy Chemin de Croix-Blanche 10 1630 Bulle - Switzerland

# Packing List / Delivery Note 81976292

SSCC (HU Identification) Material	Description Batch	Dimension Description Warehouse temperature conditions Other Storage Conditions Registered Storage Conditions	Loading weight Net weight Expiration date	Gross weight Qty material
		Store below 30°C		
180325296909503178	Pallet	80 x 120 x 110 CM	86.799	106.799 KG
CIA03691	228834	XYZAL 5MG 30TAB RB GSK MEA 15-25 °C (59-77°F) Not specified	15.574KG 31 Aug 2022	5,040 EA
		Store below 30°C		
180325296909503697	Pallet	80 x 120 x 110 CM	99.199	119.199 KG
CIA03691	226406	XYZAL 5MG 30TAB RB GSK MEA 15-25 °C (59-77°F) Not specified Store below 30°C	17.799KG 30 Jun 2022	5,760 EA
180325296909505257	Pallet	80 x 120 x 110 CM	99.199	119.199 KG
CIA03691	226406	XYZAL 5MG 30TAB RB GSK MEA 15-25 °C (59-77°F) Not specified	17.799KG 30 Jun 2022	5,760 EA
		Store below 30°C		
180325296909505585	Pallet	80 x 120 x 110 CM	99.199	119.199 KG
CIA03691	226406	XYZAL 5MG 30TAB RB GSK MEA 15-25 °C (59-77°F) Not specified	17.799KG 30 Jun 2022	5,760 EA
		Store below 30°C		
180325296909505820	Pallet	80 x 120 x 110 CM	99.199	119.199 KG
CIA03691	226406	XYZAL 5MG 30TAB RB GSK MEA 15-25 °C (59-77°F) Not specified	17.799KG 30 Jun 2022	5,760 EA
		Store below 30°C		
180325296909505950	Pallet	80 x 120 x 110 CM	99.199	119.199 KG
CIA03691	226406	XYZAL 5MG 30TAB RB GSK MEA 15-25 °C (59-77°F) Not specified Store below 30°C	17.799KG 30 Jun 2022	5,760 EA
180325296909506070	Pallet	80 x 120 x 110 CM	80.599	100.599 KG
CIA03691	226406	XYZAL 5MG 30TAB RB GSK MEA 15-25 °C (59-77°F) Not specified Store below 30°C	14.461KG 30 Jun 2022	4,680 EA



#### CERTIFICATE OF QUALITY

**UCB FARCHIM SA** Responsible Pers09 January 2018

Z.I. de Planchy Chemin de Croix Blanche 10 1630 Bulle

XYZAL (CIA03691) 5 mg 30 Tablets

complies with the required specifications as shown hereafter:

	CERTIFICATE OF ANALYSIS	N° 201701448
UCB SPECIFICATIONS PARAMETERS	SPECIFICATIONS	BATCH: 226406 RESULTS
Appearance	White to off-white, oval film-coated tablet with a Y logo on one side.	Complies
Water content	Max. 6.0% at release	4.9%
Average mass	$103 \text{ mg} \pm 7.5\%$	102 mg
Uniformity of mass	Percentage deviation: 7.5% of average mass	-3.9% + 2.1%
Identification - ucb 28556 -Titanium dioxide (E171) <sup>(a)</sup>	Positive Positive	Positive N.A.
Assay: -Levocetirizine Impurities	4.75 mg to 5.25 mg/tablet	4.87 mg/tablet
Achiral related substance: p-chlorobenzhydrylpiperazine p-chlorobenzhydrol p-chlorobenzophenone Any unspecified related substance Total related substance	Max. 0.3% Max. 0.2% Max. 0.2% Max. 0.2% Max. 0.8%	<0.10% <0.10% <0.10% Not Quantifiable Not Quantifiable
Chiral related substance: ucb 28557	Max. 2.0%	0.6%
Dissolution	Q= 75% after 30 minutes acceptance criteria USP	96% 94% 93% 96% 97% 96%
Microbiological quality(b)	(limited to stage 2) Conform to Ph Eur.(5.1.4)	N.A. 96%

(b) Test performed on one out of every ten batches

I hereby certify that all the manufacturing stages of this batch of finished product have been carried out in full compliance with the GMP requirements of the EU and with the requirements of the Marketing Authorisation(s) of the destination country/countries

Manufacturing date: 06/07/2017 Expiry date : 30/06/2022

Storage conditions: Store below 30°C

Country: Middle East

+39 011 9660 1 +39 011 9660 244

enquiries@aesica-pharma.com

Capitale Sociale: Euro 10.000,00. Registro delle imprese di Torino n° Iscrizione REA TO-1133689, C.F. e P. IVA 07235680969 Società soggetta a direzione e coordinamento da parte di Consort Medical S.r.I., Sede legale in Via Praglia n. 15, Pianezza (TO) - Italia

Aesica is a trademark of Aesica Pharmaceuticals Limited



Dr. Paolo Pizzorni

Pharmacist, Qualified Person

Aesica Pharmaceuticals S.r.l. Sede legale: Via Praglia, 15 10044 Pianezza (TO)

Italia

www.aesica-pharma.com



Z.I. de Planchy 10, Chemin de Croix Blanche P.O Box 411 CH-1630 Bulle Switzerland

## Certificate of Analysis

### Levocetirizine 2 HCl


**Batch Number** 

: 220228

**Product Code** 

: CIA30073

Test	Specification	Result
Description		
Appearance	White to off-white powder.	Complies
Solubility	Freely soluble in water, very slightly soluble in chloroform and acetone	Complies
Identifications		
IR spectrum	Complies to the reference substance	Complies
UV spectrum	Complies to the reference substance (The UV spectrum may be omitted if the IR spectrum, the chlorides and the chiral chromatography are carried out.)	Not performed routinely
Chlorides (EU)	Positive	Positive
Chlorides (US)	Positive	Positive
Chiral chromatography (EU/US)	The identification of Levocetirizine 2HCL is demonstrated if retention time does not differ from more than 3.0 % compared with the retention time of the system suitability	Complies
Chiral chromatography (JP)	The identification of Levocetirizine 2HCL is demonstrated if retention time does not differ from more than 3.0 % compared with the retention time of the system suitability	Complies
Appearance of 5% solution	Clear (opalescence lower than T1) and not more intensely colored than YB7	Complies
Water content	Not more than 1.0%	0.1 %
Sulphated ash	Not more than 0.2%	0.1 %
Heavy metals (US)	Not more than 10 ppm	Complies
Heavy metals (EU)	Not more than 10 ppm	Complies
Assay by titration (on anhydrous substance)	99.0% to 100.5%	99.8 %
Assay by HPLC (EU/US) (on anhydrous sbstance)	98.0% to 102.0%	100.0 %
Assay by HPLC (JP) (on anhydrous sbstance)	98.0% to 102.0%	99.8 %
Achiral related substances (EU/US)		
(2-(4-((2-chlorophenyl) phenylmethyl)-1-piperazinyl) ethoxy)-acetic acid	Not more than 0.2%	<0.10 %



### Levocetirizine 2 HCI

**Batch Number** 

: 220228

**Product Code** 

CIA30073

Test	Specification	Result
2-(p-chlorobenzhydryl-piperazine)- 2-ethoxyacetamide	Not more than 0.2%	<0.10 %
p-chlorobenzhydrylpiperazine	Not more than 0.2%	<0.10 %
UCB 30462	Not more than 0.2%	<0.10 %
Any unspecified impurity	Not more than 0.1%	Not Quantifiable %
Total of unspecified impurities	Not more than 0.2%	Not Quantifiable %
Total of impurities	Not more than 0.3%	Not Quantifiable %
Achiral related substances (JP)		
(2-(4-((2-chlorophenyl) phenylmethyl)-1-piperazinyl) ethoxy)-acetic acid	Not more than 0.2%	<0.10 %
2-(p-chlorobenzhydryl-piperazine)- 2-ethoxyacetamide	Not more than 0.2%	<0.10 %
p-chlorobenzhydrylpiperazine	Not more than 0.2%	<0.10 %
UCB 30462	Not more than 0.2%	<0.10 %
Any unspecified impurity	Not more than 0.1%	Not Quantifiable %
Total of unspecified impurities	Not more than 0.2%	Not Quantifiable %
Total of impurities	Not more than 0.3%	Not Quantifiable %
Chiral related substance (EU/US) UCB 28557	Not more than 2.0%	0.62 %
Chiral related substance (JP)	Not more than 2.0%	0.61 %
UCB 28557		
Residual solvents	Net was then 200 mm	12 ppm
Acetone	Not more than 300 ppm	<2 ppm
Toluene	Not more than 10 ppm	<2 ppm
Diisopropylether	Not more than 10 ppm	L. J. Marian
Mesityloxide	Not more than 20 ppm	2 ppm
рН	1.2 to 1.8	1.4
LOD	Not more than 1.0 %	Not performed routinely



Levocetirizine 2 HCI

**Batch Number** 

: 220228

**Product Code** 

· CIA30073

#### **Certification Statement:**

I hereby certify that the above information is authentic and accurate. This batch of product has been manufactured, including quality control, in full compliance with the GMP requirements of the local Regulatory Authority. The batch processing and analysis records were reviewed and found to be in compliance with GMP.

**Manufacturing Date** 

20-May-2017

Retest Date

19-May-2022

This is an electronic signature

**Issued By** 

Carole Merieux

Responsible Person Deputy

**Release Date** 

12-Jun-2017

Responsible Person

Florian Gurtler

UCB FARCHIM SA Tel: +41 26 919 02 00



#### CERTIFICATE O F

**UCB FARCHIM SA** Responsible Person deputiery 2018

Z.L. de Planchy Q U A L I T Y Chemin de Croix Blanché 10 1630 Bulle

XYZAL (CIA03691) 5 mg 30 Tablets

complies with the required specifications as shown hereafter:

	CERTIFICATE OF ANALYSIS	N° 201701402
UCB SPECIFICATIONS PARAMETERS	SPECIFICATIONS	BATCH: 228834 RESULTS
Appearance	White to off-white, oval film-coated tablet with a Y logo on one side.	Complies
Water content	Max. 6.0% at release	4.4%
Average mass	$103 \text{ mg} \pm 7.5\%$	102 mg
Uniformity of mass	Percentage deviation: 7.5% of average mass	-2.0% + 1.6%
Identification - ucb 28556 -Titanium dioxide (E171) <sup>(a)</sup>	Positive Positive	Positive N.A.
Assay: -Levocetirizine Impurities	4.75 mg to 5.25 mg/tablet	4.85 mg/tablet
Achiral related substance: p-chlorobenzhydrylpiperazine p-chlorobenzhydrol p-chlorobenzophenone Any unspecified related substance Total related substance	Max. 0.3% Max. 0.2% Max. 0.2% Max. 0.2% Max. 0.8%	<0.10% <0.10% <0.10% Not Quantifiable Not Quantifiable
Chiral related substance: ucb 28557	Max. 2.0%	0.7%
Dissolution	Q= 75% after 30 minutes acceptance criteria USP	94% 97% 100% 95% 98% 96%
Microbiological quality(b)	(limited to stage 2) Conform to Ph Eur.(5.1.4)	N.A.

(b) Test performed on one out of every ten batches (a)If tested

I hereby certify that all the manufacturing stages of this batch of finished product have been carried out in full compliance with the GMP requirements of the EU and with the requirements of the Marketing Authorisation(s) of the destination country/countries

Manufacturing date: 11/09/2017 : 31/08/2022

Storage conditions: Store below 30°C

Country: Middle East


Aesica Pharmaceuticals S.r.l. Sede legale: Via Praglia, 15 10044 Pianezza (TO)

+39 011 9660 1 +39 011 9660 244

enquiries@aesica-pharma.com

www.aesica-pharma.com

Capitale Sociale: Euro 10.000,00. Registro delle imprese di Torino nº Iscrizione REA TO-1133689, C.F. e P. IVA 07235680969 Società soggetta a direzione e coordinamento da parte di Consort Medical S.r.I., Sede legale in Via Praglia n. 15, Pianezza (TO)-Italia



Dr. Paolo Pizzorni

Pharmacist, Qualified Person



#### Levocetirizine 2 HCI

**Batch Number** 

: 220232

**Product Code** 

CIA30073

Test	Specification	Result
Description		
Appearance	White to off-white powder.	Complies
Solubility	Freely soluble in water, very slightly soluble in chloroform and acetone	Complies
Identifications		
IR spectrum	Complies to the reference substance	Complies
UV spectrum	Complies to the reference substance (The UV spectrum may be omitted if the IR spectrum, the chlorides and the chiral chromatography are carried out.)	Not performed routinely
Chlorides (EU)	Positive	Positive
Chlorides (US)	Positive	Positive
Chiral chromatography (EU/U	is demonstrated if retention time does not differ from more than 3.0 % compared with the retention time of the system suitability	Complies
Chiral chromatography (JP)	The identification of Levocetirizine 2HCL is demonstrated if retention time does not differ from more than 3.0 % compared with the retention time of the system suitability	Complies
Appearance of 5% solution	Clear (opalescence lower than T1) and not more intensely colored than YB7	Complies
Water content	Not more than 1.0%	0.0 %
Sulphated ash	Not more than 0.2%	0.0 %
Heavy metals (US)	Not more than 10 ppm	Complies
Heavy metals (EU)	Not more than 10 ppm	Complies
Assay by titration (on anhydrous substance)	99.0% to 100.5%	100.1 %
Assay by HPLC (EU/US) (on anhydrous sbstance)	98.0% to 102.0%	99.6 %
Assay by HPLC (JP) (on anhydrou sbstance) Achiral related substances (EU/US		99.3 %
(2-(4-((2-chlorophenyl) phenylmethyl)-1-piperazinyl) ethoxy)-acetic acid	Not more than 0.2%	<0.10 %



#### Levocetirizine 2 HCl


**Batch Number** 

: 220232

**Product Code** 

: CIA30073

Test	Specification	Result
2-(p-chlorobenzhydryl-piperazine)- 2-ethoxyacetamide	Not more than 0.2%	<0.10 %
p-chlorobenzhydrylpiperazine	Not more than 0.2%	<0.10 %
UCB 30462	Not more than 0.2%	<0.10 %
Any unspecified impurity	Not more than 0.1%	Not Quantifiable %
Total of unspecified impurities	Not more than 0.2%	Not Quantifiable %
Total of impurities	Not more than 0.3%	Not Quantifiable %
Achiral related substances (JP)		
(2-(4-((2-chlorophenyl) phenylmethyl)-1-piperazinyl) ethoxy)-acetic acid	Not more than 0.2%	<0.10 %
2-(p-chlorobenzhydryl-piperazine)- 2-ethoxyacetamide	Not more than 0.2%	<0.10 %
p-chlorobenzhydrylpiperazine	Not more than 0.2%	<0.10 %
UCB 30462	Not more than 0.2%	<0.10 %
Any unspecified impurity	Not more than 0.1%	Not Quantifiable %
Total of unspecified impurities	Not more than 0.2%	Not Quantifiable %
Total of impurities	Not more than 0.3%	Not Quantifiable %
Chiral related substance	Not more than 2.0%	0.74 %
(EU/US) UCB 28557		
Chiral related substance	Not more than 2.0%	0.73 %
(JP)		
UCB 28557 Residual solvents		
Acetone	Not more than 300 ppm	11 ppm
Toluene	Not more than 10 ppm	<2 ppm
Diisopropylether	Not more than 10 ppm	<2 ppm
Mesityloxide	Not more than 20 ppm	<2 ppm
pH	1.2 to 1.8	1.4
LOD	Not more than 1.0 %	Not performed routinely
		-



Levocetirizine 2 HCl

**Batch Number** 

: 220232

**Product Code** 

· CIA30073

#### **Certification Statement:**

I hereby certify that the above information is authentic and accurate. This batch of product has been manufactured, including quality control, in full compliance with the GMP requirements of the local Regulatory Authority. The batch processing and analysis records were reviewed and found to be in compliance with GMP.

**Manufacturing Date** 

29-May-2017

**Retest Date** 

28-May-2022

This is an electronic signature

Issued By

Carole Merieux

Responsible Person Deputy

**Release Date** 

19-Jun-2017

Responsible Person

Florian Gurtler

UCB FARCHIM SA Tel: +41 26 919 02 00

Page 3 of 3

Secure Report No.: 142462 LIMS Lot No.: 89336 (INTERNAL) Date: 31-Aug-2017 @15:07.57 Datasource: LBWR PROD